Combination Therapy for Alcohol Use Disorder

Part of paid clinical trials in Havre de Grace, Maryland.

Sponsor
Johns Hopkins University
Study ID
NCT07249554
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Placebo — DRUG
    Over-encapsulated non-active microcrystalline cellulose
  • Glucagon-Like Peptide-1 Agonist (GLP-1) — DRUG
    Over-encapsulated Glucagon-Like Peptide-1 Agonist (GLP-1) oral tablets
  • Naltrexone (oral tablets) — DRUG
    Over-encapsulated Naltrexone (oral tablets)

Study Details

This human laboratory study will collect preliminary safety and efficacy data from a sample of participants enrolled in a 4-week in-patient treatment program for alcohol use disorder.

Key Dates

Start date
Jul 31, 2026
Status verified
May 2026
Primary completion
Jul 31, 2028
Completion
Sep 30, 2028

Study Design

Enrollment
45 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo+Placebo
    Placebo+Placebo
  • Experimental: Placebo+GLP-1
    Placebo+GLP-1
  • Experimental: GLP-1+Naltrexone
    GLP-1+Naltrexone

Primary Outcome Measure

Participant-reported Adverse Events [ Time Frame: 14 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Ashley Addiction TreatmentHavre de GraceMaryland21078
Andrew S Huhn, Ph.D.
[email protected]
410-550-1971

Find similar trials in Havre de Grace, MD

By condition
Substance use disorder
By specialty
Behavioral healthAddiction medicine
By research site
Ashley Addiction Treatment· Havre de Grace, MD

Related Studies